Lineage Cell Therapeutics (LCTX) Cash from Investing Activities Growth (1y) (2011 - 2026)
Lineage Cell Therapeutics (LCTX) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 62.68% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -674.01% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -166.24% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 251.15 Mn | 188.44 Mn | 1.73 Mn | -222.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -222.23% |
| Dec 31, 2025 | -681.94% |
| Sep 30, 2025 | -100.31% |
| Jun 30, 2025 | 99.84% |
| Mar 31, 2025 | 5,107.89% |
| Dec 31, 2024 | -72.95% |
| Sep 30, 2024 | 83.22% |
| Jun 30, 2024 | -145.89% |
| Mar 31, 2024 | -100.25% |
| Dec 31, 2023 | 290.94% |
| Sep 30, 2023 | 105.19% |
| Jun 30, 2023 | 19,851.55% |
| Mar 31, 2023 | 33,634.78% |
| Dec 31, 2022 | -3,394.52% |
| Sep 30, 2022 | -60,067.65% |
| Jun 30, 2022 | 15.65% |
| Mar 31, 2022 | -100.46% |
| Dec 31, 2021 | -116.19% |
| Sep 30, 2021 | -138.20% |
| Jun 30, 2021 | -101.72% |